Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
Roche trims its pipeline again
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
